Anti-CD45抗体[I3/2.3] (Phycoerythrin) (ab25603)


  • 产品名称
    Anti-CD45抗体[I3/2.3] (Phycoerythrin)
    参阅全部 CD45 一抗
  • 描述
    大鼠单克隆抗体[I3/2.3] to CD45 (Phycoerythrin)
  • 偶联物
    Phycoerythrin. Ex: 488nm, Em: 575nm
  • 经测试应用
    适用于: IP, Flow Cyt, IHC-Frmore details
  • 种属反应性
    与反应: Mouse
  • 免疫原

    The details of the immunogen for this antibody are not available.

  • 表位
    ab25603 recognizes a framework epitope present on all CD45 isoforms
  • 阳性对照
    • BALB/c mouse spleen cells
  • 常规说明

    Abcam is committed to meeting high standards of ethical manufacturing and has decided to discontinue this product by July 2018 as it has been generated by the ascites method. We are sorry for any inconvenience this may cause. 


Our Abpromise guarantee covers the use of ab25603 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

应用 Ab评论 说明
IP Use at an assay dependent concentration.
Flow Cyt Use 0.2µg for 106 cells. ab136585-Rat monoclonal IgG2b, is suitable for use as an isotype control with this antibody.
IHC-Fr Use at an assay dependent concentration.


  • 功能
    Protein tyrosine-protein phosphatase required for T-cell activation through the antigen receptor. Acts as a positive regulator of T-cell coactivation upon binding to DPP4. The first PTPase domain has enzymatic activity, while the second one seems to affect the substrate specificity of the first one. Upon T-cell activation, recruits and dephosphorylates SKAP1 and FYN.
  • 疾病相关
    Defects in PTPRC are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-positive (T(-)B(+)NK(+) SCID) [MIM:608971]. A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development.
    Genetic variations in PTPRC are involved in multiple sclerosis susceptibility (MS) [MIM:126200]. MS is a neurodegenerative disorder characterized by the gradual accumulation of focal plaques of demyelination particularly in the periventricular areas of the brain. Peripheral nerves are not affected. Onset usually in third or fourth decade with intermittent progression over an extended period. The cause is still uncertain.
  • 序列相似性
    Belongs to the protein-tyrosine phosphatase family. Receptor class 1/6 subfamily.
    Contains 2 fibronectin type-III domains.
    Contains 2 tyrosine-protein phosphatase domains.
  • 结构域
    The first PTPase domain interacts with SKAP1.
  • 翻译后修饰
    Heavily N- and O-glycosylated.
  • 细胞定位
    Membrane. Membrane raft. Colocalized with DPP4 in membrane rafts.
  • Information by UniProt
  • 数据库链接
  • 别名
    • B220 antibody
    • CD 45 antibody
    • CD45 antibody
    • CD45 antigen antibody
    • CD45R antibody
    • GP180 antibody
    • L-CA antibody
    • LCA antibody
    • Leukocyte common antigen antibody
    • loc antibody
    • Ly-5 antibody
    • LY5 antibody
    • Ly5, homolog of antibody
    • Lyt-4 antibody
    • OTTHUMP00000033813 antibody
    • OTTHUMP00000033816 antibody
    • OTTHUMP00000033817 antibody
    • OTTHUMP00000038574 antibody
    • Protein tyrosine phosphatase receptor type c polypeptide antibody
    • Protein tyrosine phosphatase, receptor type C antibody
    • protein tyrosine phosphatase, receptor type, C antibody
    • Protein tyrosine phosphatase, receptor type, c polypeptide antibody
    • Ptprc antibody
    • PTPRC_HUMAN antibody
    • Receptor-type tyrosine-protein phosphatase C antibody
    • T200 antibody
    • T200 glycoprotein antibody
    • T200 leukocyte common antigen antibody
    see all


  • Flow Cytometry analysis of BALB/c mouse splenocytes labeling CD45 with ab25603 at 0.1 μg/106 cells dilution (purple). Grey - Isotype Control, Rat IgG2b-PE.

  • Flow cytometry analysis of DAPI stained alive murine cells retrivived via a bronchoaveolar lavage using PBS-EDTA 3mM, labelling CD45 with ab25603 at 1/3000 incubated for 20 minutes at 20°C in PBS-EDTA 3mM, with a primary conjugate against CD45-APC and DAPI. There was no secondary used as ab25603 is a phycoerythrin conjugate. Cells were gated on alive DAPI stained CD45+ cells. Grey histogram represents isotype control and CD45 histogram is in purple. The positive labelling of 100% CD45 + cells preselected on APC detector, confirms the efficacy of the antibody to detect CD45 antigen.

    See Abreview

  • 1 million BALB/c spleen cells were double stained with 0.3 ug of ab25603 and also a FITC labelled rat anti-mouse CD4 antibody. Small lymphocytes were gated and analysed on a flow cytometer.


This product has been referenced in:
  • Lam PK  et al. Topical Application of Mesenchymal Stromal Cells Ameliorated Liver Parenchyma Damage After Ischemia-Reperfusion Injury in an Animal Model. Transplant Direct 3:e160 (2017). Flow Cyt ; Rat . Read more (PubMed: 28620644) »
  • Chen C  et al. Efficacy of umbilical cord-derived mesenchymal stem cell-based therapy for osteonecrosis of the femoral head: A three-year follow-up study. Mol Med Rep 14:4209-4215 (2016). Flow Cyt ; Human . Read more (PubMed: 27634376) »

See all 5 Publications for this product


Flow Cytometry
Mouse Cell (Cells from bronchoalveolar lavage in balb/c mice)
Gating Strategy
alive (DAPI-),CD45+ cells
Cells from bronchoalveolar lavage in balb/c mice
Cell harvesting/tissue preparation method: Bronchoaveolar lavage in balb/c mice was performed with PBS-EDTA 3mM
Sample buffer: PBS-EDTA 3mM

Dr. Francois Daubeuf

Verified customer

提交于 Sep 29 2015

Thank you for contacting us. I am sorry to hear that this antibody is giving problems. I checked the literature and found the following publication showing that CD45 can be expressed on mouse MSC in early stages: Med J Malaysia. 2008 Jul;63 Supp...

Read More